Ventyx Biosciences/VTYX

$2.99

19.91%
-
1D1W1MYTD1YMAX

About Ventyx Biosciences

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX958 (TYK2 Inhibitor), VTX002 (S1P1R Modulator), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor.
Ticker
VTYX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Raju Mohan
Employees
99
Headquarters
San diego, United States

VTYX Metrics

BasicAdvanced
$145.26M
Market cap
-
P/E ratio
-$3.12
EPS
-
Beta
-
Dividend rate

What the Analysts think about VTYX

Analyst Ratings

Majority rating from 10 analysts.
Hold

Price Targets

Average projection from 8 analysts.
180.27% upside
High $21.00
Low $2.00
$2.99
Current price
$8.38
Average price target

VTYX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-54M
1.5%
Profit margin
0%
-

VTYX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 2.73%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.62
-$0.68
-$0.91
-$0.92
-
Expected
-$0.63
-$0.65
-$0.71
-$0.90
-$0.90
Surprise
-0.83%
4.97%
27.97%
2.73%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Ventyx Biosciences stock

Buy or sell Ventyx Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing